Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    FDA says Novo Nordisk’s obesity pill TV ad includes misleading claims

    AdminBy AdminFebruary 10, 2026 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    FDA says Novo Nordisk’s obesity pill TV ad includes misleading claims

    Inside the legal fight slowing down cheaper GLP-1 drugs

    The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine’s abilities and benefits to patients.

    In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims. 

    In a statement Monday, Novo Nordisk confirmed that it received the letter and clarified that the ad has been running since the pill’s launch, but is not the company’s Super Bowl spot.

    “We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” Liz Skrbkova, Novo’s head of U.S. media and stakeholder relations, said in the statement. 

    It adds to the mounting hurdles the Danish drugmaker is facing as it scrambles to win back market share from chief rival Eli Lilly and cheaper compounded copycats in the booming GLP-1 market. 

    The company’s Wegovy pill is key to those efforts. It was the first-ever GLP-1 pill for obesity to enter the market in January, and Novo last week said more than 170,000 American patients are already taking the drug. 

    Bloomberg first reported on the FDA letter on Monday.

    More CNBC health coverage

    In the letter, the FDA said Novo’s ad misleadingly suggests its pill offers superior benefits to other approved GLP-1 weight loss drugs. The agency said phrases used in the spot, including “live lighter” and “a way forward,” imply greater weight loss than other treatments and added benefits beyond that, despite no evidence to support those claims. 

    The ad’s statements “misleadingly imply benefits beyond physical weight loss such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific condition, when this has also not been demonstrated,” the FDA said in the letter. 

    The FDA also flagged the ad for failing to properly present risk information in both audio and text, a requirement for television drug advertising. 

    Also on Monday, Novo Nordisk sued Hims & Hers, asking the court to stop the telehealth company from mass marketing compounded versions of its Wegovy pill and injections. 

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Over 314,000 older Toyota and Lexus vehicles recalled for potentially dangerous airbag issue

    November 20, 2026

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026
    Popular Posts

    Bruno Mars Mourns His Fathers Death: The Man That Taught Me Everything I Know

    RHONJ Fans Less Than Impressed With Season 15 Sneak Peek

    Director Steve Miner Has Shot New Friday the 13th Movie

    JPMorganChase reports cyberattack on third-party service providers

    Fantasy and Science Fiction Books Where the Rules Dont Apply – NewInBooks

    Book Riots Deals of the Day for November 19, 2026

    Categories
    • Books (2,459)
    • Business (3,450)
    • Events (34)
    • Film (1,064)
    • LifeStyle (2,924)
    • Music (2,798)
    • Politics (2,356)
    • Science (1,954)
    • Technology (1,819)
    • Television (3,630)
    • US News (3,295)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Daredevil: Born Again: Everything We Know So Far About the Superhero RevivalDaredevil: Born Again: Everything We Know So Far About the Superhero Revival
    • Canada, Mexico and China respond to Trump’s tariffsCanada, Mexico and China respond to Trump’s tariffs
    • Autumn Reeser on How Your Inner Child and Playfulness Relate to Hallmark’s JunebugAutumn Reeser on How Your Inner Child and Playfulness Relate to Hallmark’s Junebug
    • Here’s what Morrissey played at his Hollywood Palladium New Year’s Eve showHere’s what Morrissey played at his Hollywood Palladium New Year’s Eve show
    • Trump heads to Turkey for NATO summit as Russia attacks UkraineTrump heads to Turkey for NATO summit as Russia attacks Ukraine
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.